SEARCH

SEARCH BY CITATION

6.4 References

  • 1
    Bower M, Collins S, Cottrill C et al. AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9: 336388.
  • 2
    Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61: 310316.
  • 3
    Gilden DH, Kleinschmidt-DeMaster BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342: 635645.
  • 4
    Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155: 16051609.
  • 5
    Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 920.
  • 6
    Glesby MJ, Hoover DR, Tan T et al. Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37: 16041609.
  • 7
    Buchbinder SP, Katz MH, Hessol NA et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166: 11531156.
  • 8
    Veenstra J, Krol A, van Praag RM et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995; 9: 11531158.
  • 9
    Engels EA, Rosenberg PS, Biggar RJ. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984–1997. J Infect Dis 1999; 180: 17841789.
  • 10
    Gebo KA, Kalyani R, Moore RD, Polydefkis M. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005; 40: 169174.
  • 11
    Colebunders R, Mann JM, Francis H et al. Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection. J Infect Dis 1988; 157: 314318.
  • 12
    Glesby MJ, Moore RD, Chaisson RE. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. J Infect Dis 1993; 168: 12641268.
  • 13
    Pahwa S, Biron K, Lim W et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988; 260: 28792882.
  • 14
    Jacobson MA, Berger TG, Fikrig S et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 187191.
  • 15
    Tangsinmankong N, Kamchaisatian W, Lugan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol 2004; 113: 742746.
  • 16
    Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001; 110: 605609.
  • 17
    Gray F, Bélec L, Lescs MC et al. Varicella-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome. Brain 1994; 117: 987999.
  • 18
    Coffin SE, Hodinka RL. Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin lesions. J Clin Microbiol 1995; 33: 27922795.
  • 19
    Espy MJ, Teo R, Ross TK et al. Diagnosis of varicella-zoster virus infections in the clinical laboratory by LightCycler PCR. J Clin Microbiol 2000; 38: 31873189.
  • 20
    Schmutzhard J, Merete Riedel H, Zweygberg Wirgart B, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004; 29: 120126.
  • 21
    De La Blanchardiere A, Rozenberg F, Caumes E, Picard O, Lionnet F, Livartowski J, Coste J, Sicard D, Lebon P, Salmon-Cèron D. Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand J Infect Dis 2000; 32: 263269.
  • 22
    Brown M, Scarborough M, Brink N, Manji H, Miller R. Varicella zoster virus-associated neurological disease in HIV-infected patients. Int J STD AIDS 2001; 12: 7983.
  • 23
    Corral I, Quereda C, Antela A et al. Neurological complications of varicella-zoster virus in human immunodeficiency virus-infected patients: changes in prevalence and diagnostic utility of polymerase chain reaction in cerebrospinal fluid. J Neurovirol 2003; 9: 129135.
  • 24
    Minjolle S, Arvieux C, Gautier AL et al. Detection of herpesvirus genomes by polymerase chain reaction in cerebrospinal fluid and clinical findings. J Clin Virol 2002; 25 (Suppl. 1): S5970.
  • 25
    Dworkin RH, Johnson RW, Breuer J et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 (Suppl. 1): S1S26.
  • 26
    Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children: a collaborative study. J Pediatr 1982; 101: 622625.
  • 27
    Carcao MD, Lau RC, Gupta A, Huerter H, Koren G, King SM. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatr Infect Dis J 1998; 17: 626631.
  • 28
    Sullivan M, Skiest D, Signs D, Young C. Famciclovir in the management of acute herpes zoster in HIV+ patients. 4th Conference on Retroviruses and Opportunistic Infections. January 1997, Washington DC, USA. Abstract 704.
  • 29
    Brentjens MH, Torres G, He J, Lee PC, Tyring SK. A double-blind randomized study of the use of 2 grams vs. 1 gram valacyclovir TID for 7 days in the treatment of acute herpes zoster in immunocompromised individuals. 61st Annual Meeting of the American Academy of Dermatology, March 2003, San Francisco, CA, USA. Abstract P455.
  • 30
    Balfour HH Jr, Bean B, Laskin OL et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 14481453.
  • 31
    Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314: 208212.
  • 32
    Safrin S, Berger TG, Gilson I et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991; 115: 1921.
  • 33
    Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis 1998; 27: 15251527.
  • 34
    Geretti AM on behalf of the BHIVA Immunization Writing Committee. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795848.
  • 35
    Safrin S, Ashley R, Houlihan C, Cusick PS, Mills J. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS 1991; 5: 11071110.
  • 36
    Stewart JA, Reef SE, Pellett PE, Corey L, Whitley RJ. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 (Suppl. 1): S114S120.
  • 37
    Quinnan GV Jr, Masur H, Rook AH et al. Herpes virus infections in the acquired immunodeficiency syndrome. JAMA 1984; 252: 7277.
  • 38
    Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178: 16161622.
  • 39
    Bagdades EK, Pillay D, Squire SB, O'Neil C, Johnson MA, Griffiths PD. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS 1992; 6: 13171320.
  • 40
    Wright PW, Hoesley CJ, Squires KE, Croom-Rivers A, Weiss HL, Gnann JW Jr A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis 2003; 36: 207211.
  • 41
    Weiss H. Epidemiology of herpes simplex virus type 2 in the developing world. Herpes 2004; 11 (Suppl. 1): 24A35A.
  • 42
    Russell DB, Tabrizi SN, Russell JM, Garland SM. Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting. J Clin Virol 2001; 22: 305313.
  • 43
    Ramaswamy M, Sabin C, McDonald C, Smith M, Taylor C, Geretti AM. Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons. Sex Transm Dis 2006; 33: 96101.
  • 44
    Celum C, Levine R, Weaver M, Wald A. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 2004; 82: 447453.
  • 45
    Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185: 4552.
  • 46
    Barton S, Celum C, Shacker TW. The role of anti-HSV therapeutics in the HIV-infected host and in controlling the HIV epidemic. Herpes 2005; 12: 1522.
  • 47
    Clinical Effectiveness Group, British Association for Sexual Health and HIV.. 2007 National Guideline for the Management of Genital Herpes. Available at http://www.bashh.org/documents/115/115.pdf (last accessed 29 September 2009).
  • 48
    Tyring SK, Carlton SS, Evans T. Herpes. Atypical clinical manifestations. Dermatol Clin 1998; 16: 783788, xiii.
  • 49
    Mosunjac M, Park J, Wang W et al. Genital and perianal herpes simplex simulating neoplasia in patients with AIDS. AIDS Patient Care STDS 2009; 23: 153158.
  • 50
    Corey L. Genital herpes, In: Sexually Transmitted Diseases Holmes KK, Mårah P-A, Sparling PF. eds. 2nd edn. New York: McGraw-Hill, 1990: 391413.
  • 51
    Thin RN. Management of genital herpes infections. Am J Med 1988; 85: 36.
  • 52
    Posavad CM, Wald A, Kuntz S et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004; 190: 693696.
  • 53
    Fox PA, Barton SE, Francis N et al. Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999; 1: 1018.
  • 54
    Nadal SR, Calore EE, Manzione CR, Horta SC, Ferreira AF, Almeida LV. Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum 2005; 48: 22892293.
  • 55
    Kinghorn GR. Genital herpes: natural history and treatment of acute episodes. J Med Virol 1993; Suppl 1: 3338.
  • 56
    Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect 2002; 78: 2125.
  • 57
    Espy MJ, Uhl JR, Mitchell PS et al. Diagnosis of herpes simplex virus infections in the clinical laboratory by LightCycler PCR. J Clin Microbiol 2000; 38: 795799.
  • 58
    Ashley RL. Laboratory techniques in the diagnosis of herpes simplex infection. Genitourin Med 1993; 69: 174183.
  • 59
    Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35 (Suppl. 2): S173S182.
  • 60
    Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001; 77: 232237.
  • 61
    Momméja-Marin H, Lafaurie M, Scieux C, Galicier L, Oksenhendler E, Molina JM. Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adults. Clin Infect Dis 2003; 37: 15271533.
  • 62
    Boivin G. Diagnosis of herpes viruses infection of the central nervous system. Herpes 2004; 11 (Suppl. 2): 47AA.
  • 63
    Grover D, Newsholme W, Brink N, Manji H, Miller R. Herpes simplex virus infection of the central nervous system in human immunodeficiency virus-type 1-infected patients. Int J STD AIDS 2004; 15: 597600.
  • 64
    Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. AIDS 2000; 14: 12111217.
  • 65
    DeJesus E, Wald A, Warren T et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 10091016.
  • 66
    Centers for Disease Control and PreventionWorkowski KA, Berman SM Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55 (RR-11): 194.
  • 67
    Ameli N, Bacchetti P, Morrow RA et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20: 10511058.
  • 68
    Ioannidis JP, Collier AC, Cooper DA et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178: 349359.
  • 69
    Schacker T, Hu HL, Koelle DM et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 2128.
  • 70
    Conant MA, Schacker TW, Murphy RL et al. International Valaciclovir HSV Study Group Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13: 1221.
  • 71
    Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002; 34: 944948.
  • 72
    Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996; 156: 17291735.
  • 73
    Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study. JAMA 1996; 276: 4449.
  • 74
    Binetruy C, Deback C, Roubaud-Baudron C, Agut H, Bricaire F, Bossi P. Herpes simplex virus meningitis in 11 patients. Med Mal Infect 2008; 38: 141145.
  • 75
    Tyler KL. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes 2004; 11 (Suppl. 2): 57A64A.
  • 76
    Erlich KS, Mills J, Chatis P et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293296.
  • 77
    Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163: 7680.
  • 78
    Smith NA, Wood C, Asboe D, Bingham JS. Topical foscarnet for aciclovir-resistant mucocutaneous herpes infections in AIDS. AIDS 1997; 11: 254255.
  • 79
    Javaly K, Wohlfeiler M, Kalayjian R et al. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. J Acquir Immune Defic Syndr 1999; 21: 301306.
  • 80
    Lalezari J, Schacker T, Feinberg J et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997; 176: 892898.
  • 81
    Safrin S, Crumpacker CS, Chatis PA et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325: 551555.
  • 82
    Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992: 92 (2A): 30S–35S.
  • 83
    Snoeck R, Andrei G, Gérard M et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994; 18: 570578.
  • 84
    Saint-Léger E, Fillet AM, Malvy D, Rabanel B, Caumes E. Efficacy of cidofovir in an HIV infected patient with an acyclovir and foscarnet resistant herpes simplex virus infection. Ann Dermatol Venereol 2001; 128: 747749.